Twitter Facebook LinkedIn YouTube

Private Placement: Lumiera Health (TSXV:NHP)

Video Platform Video Management Video Solutions Video Player

The company is looking to raise gross proceeds of up to $1.3 million from the placement of up to 52 million units priced at $0.025 per unit. The units consist of 1 share and 1 warrant, with the warrant exercisable at $0.06 for 48 months, subject to an acceleration clause.

Additional Information:

Company: Lumiera Health
Website: http://www.lumiera.ca
Stock Symbol: TSXV: NHP
Date Published: Jun 18, 2021
Transcript: Available

Video Transcript:

I’m Cassandra Bolinski for Investmentpitch Media

Lumiera Health, which specializes in the development and commercialization of natural products for consumer health care, has announced a non-brokered private placement.

The company is looking to raise gross proceeds of up to $1.3 million from the placement of up to 52 million units priced at $0.025 per unit.

The units consist of 1 share and 1 warrant, with the warrant exercisable at $0.06 for 48 months, subject to an acceleration clause.

The shares are currently trading at $0.035.

Carlos Ponce, CEO, stated: “We have made great progress in the past couple of months and the added capital will enable us to accelerate our growth as we continue on our expected path toward profitability."

The company completed development of three sleep products targeting Sleep Onset, Sleep Anxiety, and Sleep Maintenance under its Bazzzics™ brand.

In November 2020, the company finalized its stability test of the products as well as all the marketing and promotion materials and the products were launched in its distribution channel in December 2020.

According to a March 2021 Research Report by Facts and Factors, “The global Sleeping Aids Market was estimated at USD 64.29 Billion in 2019 and is expected to reach USD 101.7 Billion by 2026. The global Sleeping Aids Market is expected to grow at a compound annual growth rate of 6.7% from 2019 to 2026”.

On April 5th, 2021, the company announced the launch of Awaye pain relief cream for the Canadian market.

Awaye provides a new generation of relief from acute and chronic pain by exploiting the CB2 receptors of the
endocannabinoid system, the body's built in pain and inflammation defense system.

The company has also advanced other products in its pipeline by obtaining Natural Health Product numbers from Health Canada including a three-product approach to juvenile acne, namely a natural based Acne Cleanser, Acne Toner and Acne Anti-infective.

Lumiera has filed applications for 4 patents and has 56 Natural Product Numbers registered with Health Canada in its product portfolio and intends to leverage these assets through new product launches and licensing deals in various channels and market segments.

For more information, please visit the company’s website at www.lumiera.ca, contact Simon Castonguay CFO, at 514-880-7772 or by email at scastonguay@lumiera.ca.

I’m Cassandra Bolinski for Investmentpitch Media